We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+5.39%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
-$169M
(-10%)
Cap. Flow
-$49.5M
Cap. Flow
% of AUM
-3.29%
Top 10 Holdings %
Top 10 Hldgs %
63.08%
Holding
56
New
8
Increased
10
Reduced
5
Closed
4
Avg Time Held Equity + Options
1
year
Top 10 Avg Time Held Equity + Options
0.8
years
Top 20 Avg Time Held Equity + Options
0.9
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$57.8M |
| 2 |
Apellis Pharmaceuticals
APLS
|
+$27M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$25.5M |
| 4 |
BridgeBio Pharma
BBIO
|
+$20.9M |
| 5 |
AN2 Therapeutics
ANTX
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$167M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$58.8M |
| 3 |
Morphic Holding, Inc. Common Stock
MORF
|
+$15.2M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$10.2M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$6.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.83% |
| 2 | Miscellaneous | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Passage Bio
PASG
$11.6M
| $1.16M | 0.08% |
87,911
-4,589
| -5% | -$75.4K |
2022 Q1
6 quarters
|
|
52
NewAmsterdam Pharma Warrant
NAMSW
| $951K | 0.06% |
500,333
| – | – |
2022 Q4
3 quarters
|
|
53
Immunovant
IMVT
$5.68B
| – | – |
-300,000
| Closed | -$5.69M | – |
|
|
54
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| – | – |
-265,511
| Closed | -$15.2M | – |
|
|
RETA
55
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-100,430
| Closed | -$10.2M | – |
|
|
KDNY
56
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – |
-4,345,559
| Closed | -$167M | – |
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q3 2023 Portfolio in Review
As of Q3 2023, Frazier Life Sciences Management held 56 positions worth $1.51B, down 10% from $1.67B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Frazier Life Sciences Management withdrew a net $49.5M in Q3 2023, closing 4 positions and reducing 5 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $167M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
Against the trend, Frazier Life Sciences Management opened a new position in Apellis Pharmaceuticals worth $23.4M.
- Frazier Life Sciences Management's largest Q3 2023 buy was Apellis Pharmaceuticals: 614,043 shares worth $23.4M.
- Frazier Life Sciences Management added most to Mirum Pharmaceuticals in Q3 2023, an estimated $57.8M increase.
- Frazier Life Sciences Management's biggest Q3 2023 reduction was Syndax Pharmaceuticals, cutting an estimated $58.8M.
- Frazier Life Sciences Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $167M.
- Frazier Life Sciences Management's ten largest holdings make up 63% of its $1.51B portfolio in Q3 2023.
- Frazier Life Sciences Management opened 8 new positions and closed 4 in Q3 2023.
- Frazier Life Sciences Management's portfolio value fell 10% quarter-over-quarter to $1.51B.
Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.